Original Article

Influence of pT3 Subgroups on Outcome of R0-Resected Colorectal Tumors

Authors: Karl Mrak, MD, MSc, Michael Jagoditsch, MD, Sebastian Leibl, MD, Anton Klingler, PhD, Jörg Tschmelitsch, MD, FACS

Abstract

Objective: Evaluate whether depth of infiltration within T3 colorectal tumors influences long-term oncologic outcome.


Patients and Methods: Patients with stage pT3 colon and rectal tumors were divided into four subgroups according to the depth of infiltration. The influence on overall and disease-free survival was tested for each subgroup and compared in univariate and multivariate analyses.


Results: A total of 368 patients were evaluated, with a median follow-up time of 92.5 months. In 181 patients with colon cancer 5- and 10-year overall survival rates were 82.7% and 65.0%, respectively, and 5- and 10-year disease-free survival rates were 80.9% and 64.4%, respectively. For 187 patients, rectal cancer 5- and 10-year overall survival rates were 69.0% and 50.5%, respectively, and disease-free survival rates were 61.3% and 47.5%, respectively. In either colon or rectal cancer, different pT3 categories showed neither a statistically significant influence on survival nor the occurrence of local or distant recurrence in univariate and multivariate analyses; however, higher pT3 subgroups had a significant influence on lymph node involvement and vessel invasion in patients with rectal cancer.


Conclusions: Subdivision of pT3 tumors in colon cancer based on depth of infiltration does not provide additional information about prognosis. In rectal cancer, T3 substages were associated with lymph node involvement; however, we could not demonstrate an impact on recurrence or survival.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Merkel S, Mansmann U, Papadopoulos T, et al. The prognostic inhomogeneity of colorectal carcinomas stage III. A proposal for subdivision of stage III. Cancer 2001;92:2754-2759.
 
2. Miyoshi M, Ueno H, Hashiguchi Y, et al. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg 2006;243:492-498.
 
3. Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999;42:167-173.
 
4. Burdy G, Panis Y, Alves A, et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-1688.
 
5. Tsai HL, Cheng KI, Lu CY, et al. Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection. J Surg Oncol 2008;97:383-387.
 
6. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-994.
 
7. Steel MC, Woods R, Mackay JM, et al. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg 2002;72:483-487.
 
8. Cawthorn SJ, Parums DV, Gibbs NM, et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet 1990;335:1055-1059.
 
9. Katsumata D, Fukui H, Ono V, et al. Depth of tumor invasion in locally advanced rectal cancer correlates with patients prognosis: the usefulness of elastic stain for its measurement. Surg Today2008;8:115-122.
 
10. Picon AI, Moore HG, Sternberg SS, et al. Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis 2003;18:487-492.
 
11. Yoshida K, Yoshimatsu K, Otani T, et al. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res2008;28:1773-1778.
 
12. Hermanek P, Henson DE, Hutter RVP, et al, eds. International Union Against Cancer (UICC): TNM Supplement 1993. A Commentary on Uniform Use. Berlin, Germany. Springer Verlag; 1993:122.
 
13. Jagoditsch M, Lisborg P, Jatzko GR, et al. Long-term prognosis for colon cancer related to consistent radical surgery: multivariate analysis of clinical, surgical and pathologic variables. World J Surg 2000;24:1264-1270.
 
14. Schippinger W, Samonigg H, Schaberl-Moser R, et al. Austrian Breast and Colorectal Cancer Study Group. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007;97:1021-1027.
 
15. Schippinger W, Jagoditsch M, Sorré C, et al. Austrian Breast and Colorectal Cancer Study Group. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer 2005;92:1655-1662.
 
16. Fielding LP, Arsenault PA, Chapuis PH, et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991;6:325-344.
 
17. Jagoditsch M, Pozgainer P, Klingler A, et al. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum 2006;49:1116-1130.
 
18. Sauer R, Fietkau R, Wittekind C, et al. German Rectal Cancer Group. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 2003;5:406-415.
 
19. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
 
20. Li M, Li JY, Zhao AL, Gu J. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology 2007;73:52-57.
 
21. Merkel S, Mansmann U, Siassi M, et al. The prognostic inhomogeneity in pT3 rectal carcinomas.Int J Colorectal Dis 2001;16:298-304.
 
22. Harewood GC, Kumar KS, Clain JE, et al. Clinical implications of quantification of mesorectal tumor invasion by endoscopic ultrasound: all T3 rectal cancers are not equal. J Gastroenterol Hepatol2004;19:750-755.
 
23. Shinto E, Ueno H, Hashiguchi Y, et al. The subserosal elastic lamina: an anatomic landmark for stratifying pT3 colorectal cancer. Dis Colon Rectum 2004;47:467-473.
 
24. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416-421.
 
25. Eriksen MT, Wibe A, Haffner J, Wiig JN. Norwegian Rectal Cancer Group. Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum2007;50:156-167.